CJC-1295 No DAC + Ipamorelin Stack Research Guide: Mechanisms, GH Pulse Synergy & Laboratory Applications 2026

The CJC-1295 No DAC + Ipamorelin stack has become one of the most widely referenced growth hormone secretagogue combinations in peptide research. By pairing a GHRH analogue with a selective ghrelin receptor agonist, investigators have constructed a dual-receptor model for studying amplified, physiologically patterned GH pulses in preclinical settings. Understanding how each component contributes mechanistically — and how their interaction produces synergistic outcomes — has made this combination a cornerstone subject in laboratory GH axis research through 2026.

In this guide, we break down the biochemistry of each peptide, examine what preclinical studies have observed about their combined signaling, and outline the laboratory parameters researchers typically explore when working with this stack.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

Ipamorelin — 10MG

Ipamorelin - 10MG — Research-Grade Reference Material Ipamorelin - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$55.00 ($41.25 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is the CJC-1295 No DAC + Ipamorelin stack?

This stack pairs CJC-1295 No DAC (a GHRH analogue also known as Mod GRF 1-29) with Ipamorelin (a selective GHRP/ghrelin receptor agonist). In preclinical research, the combination has been studied for its ability to engage two complementary receptor pathways — GHRH-R and GHSR-1a — simultaneously, producing amplified and pulsatile GH release patterns compared to either peptide alone.

What is the difference between CJC-1295 No DAC and CJC-1295 with DAC?

CJC-1295 No DAC (Mod GRF 1-29) has a shorter half-life of approximately 30 minutes, producing a sharp, transient GH pulse that more closely mimics endogenous GHRH signaling. CJC-1295 with DAC includes a Drug Affinity Complex that extends half-life to several days via albumin binding, producing a more sustained elevation. Researchers select between them depending on whether pulsatile or continuous GH release models are the study objective. A detailed breakdown is available in the CJC-1295 with DAC vs without DAC research guide.

How does Ipamorelin differ from other GHRPs?

Ipamorelin is notable for its high selectivity at the GHSR-1a receptor with minimal effect on cortisol, prolactin, or ACTH in research models — a profile that distinguishes it from earlier GHRPs such as GHRP-2 and GHRP-6. This selectivity has made it a preferred research tool when investigators want to isolate GH-axis signaling without confounding hormonal side effects.

Why do researchers combine CJC-1295 No DAC with Ipamorelin?

The two peptides act on different but complementary receptors. CJC-1295 No DAC stimulates the GHRH receptor (GHRH-R), increasing cAMP and promoting GH synthesis. Ipamorelin stimulates GHSR-1a, amplifying GH release through a separate signaling cascade involving phospholipase C and intracellular calcium. Studies suggest the combination produces a synergistic GH pulse significantly greater than either peptide administered alone.

What has preclinical research observed about this stack and IGF-1?

Several animal studies have reported that sustained activation of the GH axis via GHRH/GHRP combinations corresponds with downstream elevations in IGF-1, a key growth factor involved in cellular proliferation, protein synthesis, and tissue remodeling. Researchers studying tissue repair, muscle metabolism, and metabolic adaptation often track IGF-1 as a downstream biomarker in GH axis research.

Is the CJC-1295 No DAC + Ipamorelin stack safe for human use?

This content is strictly for research purposes. These peptides are investigated in preclinical and laboratory settings. No safety or efficacy conclusions for human use should be drawn from this guide. Researchers should consult all applicable regulatory guidelines before handling these compounds.

What delivery formats are available for researchers studying this combination?

Research-grade CJC-1295 No DAC and Ipamorelin are available in blended nasal spray formulations as well as separate lyophilized powder formats, depending on the delivery model being studied. Nasal spray formats are being explored in research for their non-injectable intranasal delivery characteristics.

CJC-1295 No DAC: Mechanism of Action in GH Axis Research

CJC-1295 No DAC — formally known as Modified GRF 1-29 or Mod GRF 1-29 — is a truncated and stabilized analogue of endogenous growth hormone-releasing hormone (GHRH). Native GHRH is a 44-amino-acid peptide, but research has demonstrated that the first 29 amino acids contain the biologically active core. However, the native 1-29 sequence degrades rapidly in plasma, primarily via dipeptidyl peptidase IV (DPP-IV) cleavage. CJC-1295 No DAC incorporates four amino acid substitutions that confer enzymatic resistance while preserving GHRH receptor binding affinity.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

Ipamorelin — 10MG

$55.00 ($41.25 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

At the cellular level, CJC-1295 No DAC binds the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary. Receptor activation couples to Gs proteins, increasing intracellular cAMP and activating protein kinase A (PKA). This signaling cascade promotes both GH gene transcription and the exocytosis of pre-synthesized GH vesicles, producing a rapid and pronounced GH pulse. Because CJC-1295 No DAC lacks the Drug Affinity Complex (DAC) albumin-binding moiety, its half-life remains approximately 30 minutes — creating a sharp, time-limited pulse that researchers use to model physiologically authentic GH secretion events.

Pharmacokinetic Profile and Research Relevance

The short half-life of CJC-1295 No DAC is considered a research advantage in studies designed to examine episodic GH release. Compared to CJC-1295 with DAC, which produces a prolonged GH “bleed,” the No DAC variant allows investigators to time administration precisely and measure discrete GH pulse amplitudes and durations. This makes it particularly useful in pulsatility research, circadian GH rhythm studies, and models where dose-response relationships are being characterized.

CJC 1295 No DAC + Ipamorelin 10MG Nasal Spray for research →

Ipamorelin: Selective GHSR-1a Agonism and Research Profile

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a member of the growth hormone-releasing peptide (GHRP) family. It acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a), a G-protein coupled receptor predominantly expressed on pituitary somatotrophs and in the hypothalamus. As researchers have noted in the Ipamorelin nasal spray research guide, its selectivity profile has made it a preferred peptide in GH-axis studies.

Unlike earlier GHRPs such as GHRP-2 and GHRP-6, which nonselectively activate multiple receptor pathways and elevate cortisol, prolactin, and ACTH in research models, Ipamorelin demonstrates a markedly cleaner binding profile. In vitro and animal studies have consistently shown that Ipamorelin produces dose-dependent GH release with minimal stimulation of the hypothalamic-pituitary-adrenal (HPA) axis — a property that makes it highly valuable for isolated GH-axis research without hormonal confounders.

Cellular Signaling Pathway

GHSR-1a activation by Ipamorelin couples to Gq/11 proteins, activating phospholipase C (PLC), which generates IP3 and DAG as second messengers. IP3 triggers intracellular calcium mobilization from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The resulting calcium transient is a direct trigger for GH vesicle exocytosis from pituitary somatotrophs. This Gq-mediated mechanism is distinct from — and complementary to — the Gs/cAMP pathway activated by GHRH-R, which is precisely why the two pathways are studied in combination.

Ipamorelin 10MG Nasal Spray for research →

The Synergistic Mechanism: Why This Stack Is a Research Priority

The fundamental scientific rationale for combining CJC-1295 No DAC and Ipamorelin lies in the dual-receptor convergence on pituitary somatotrophs. Each peptide operates through a mechanistically independent pathway — GHRH-R/Gs/cAMP for CJC-1295 No DAC, and GHSR-1a/Gq/calcium for Ipamorelin — yet both converge on the same effector output: GH secretion. Research has explored whether simultaneous activation of both pathways produces additive or synergistic results.

Studies in rodent models have demonstrated that the co-administration of GHRH analogues with GHRPs produces GH pulses substantially larger than the sum of each peptide’s individual effect — a hallmark of true pharmacological synergy. The mechanistic basis appears to involve cross-talk between the cAMP and calcium second messenger systems within somatotrophs: cAMP sensitizes the calcium secretory machinery, meaning that when both signals arrive simultaneously, GH exocytosis is amplified beyond what either signal alone could achieve.

This synergistic output has made the CJC-1295 No DAC + Ipamorelin combination a reference model in GH pulsatility research, somatotroph biology studies, and preclinical investigations of the GH/IGF-1 axis — areas that are directly related to the IGF-1 LR3 research landscape as well.

Timing Considerations in Research Models

Because CJC-1295 No DAC has a half-life of approximately 30 minutes, research protocols often administer both peptides simultaneously to achieve peak receptor occupancy overlap. The sharp GHRH-R signal provides GH synthesis stimulation, while the GHSR-1a signal from Ipamorelin amplifies the secretory event. Studies have found that timing synchrony between the two peptides is a key variable in maximizing observable GH pulse amplitude — a nuance that informs experimental design in laboratory settings.

⚡ UNLOCK 25% OFF YOUR FIRST ORDER

Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.

For research use only. No spam — unsubscribe anytime.

Downstream Research Targets: IGF-1, Tissue Metabolism & Body Composition Models

In preclinical research, the primary downstream biomarker studied following GH axis activation is insulin-like growth factor 1 (IGF-1), primarily produced in the liver in response to GH stimulation. IGF-1 mediates many of GH’s anabolic and metabolic effects at peripheral tissues, and its elevation has been used as a validated proxy for GH axis activation in animal models.

Research using GHRH/GHRP combinations has investigated several downstream biological phenomena:

Muscle protein synthesis: Animal models have examined whether GH/IGF-1 elevation following GHRH+GHRP administration correlates with enhanced nitrogen retention and skeletal muscle hypertrophy markers.
Adipose tissue lipolysis: GH is a well-characterized lipolytic hormone; preclinical studies have observed changes in adipose tissue mass and fatty acid mobilization in response to GH secretagogue administration.
Bone mineral density: GH/IGF-1 signaling is a known regulator of osteoblast activity; some studies have examined bone density parameters in animal GH deficiency models treated with GH secretagogue combinations.
Recovery and tissue repair: Overlap exists between GH-axis research and tissue repair models — researchers studying regenerative peptide stacks such as those explored in the GLOW stack research guide have noted complementary mechanisms when GH-axis peptides are incorporated into broader regenerative research protocols.
Metabolic rate and energy expenditure: GH has direct effects on insulin sensitivity and substrate utilization; metabolic chamber studies in rodents have characterized energy expenditure changes following secretagogue administration.

Comparison: CJC-1295 No DAC + Ipamorelin Stack vs Individual Components

Feature	CJC-1295 No DAC (Alone)	Ipamorelin (Alone)	CJC-1295 No DAC + Ipamorelin (Stack)
Primary receptor target	GHRH-R	GHSR-1a	GHRH-R + GHSR-1a (dual)
Second messenger pathway	Gs/cAMP/PKA	Gq/PLC/Ca²⁺	Both pathways simultaneously
GH pulse amplitude (preclinical)	Moderate	Moderate	Synergistically amplified
Half-life	~30 minutes	~2 hours	Governed by individual components
Cortisol/ACTH stimulation	Minimal	Minimal (high selectivity)	Minimal — preserved selectivity
Pulsatility pattern	Physiological pulse	Physiological pulse	Amplified physiological pulse
IGF-1 elevation (preclinical)	Moderate downstream increase	Moderate downstream increase	Greater downstream IGF-1 observed
Research use case	GHRH-R signaling studies	GHSR-1a selectivity studies	GH axis synergy, metabolic research

CJC-1295 No DAC + Ipamorelin vs CJC-1295 with DAC: Research Design Considerations

Choose CJC-1295 No DAC + Ipamorelin if…

Your research model requires pulsatile, physiologically timed GH release events
You are studying acute GH pulse amplitude and somatotroph secretory capacity
Your protocol examines circadian GH rhythmicity or meal-entrained GH pulses
You want a clean hormonal background with minimal cortisol or prolactin interference
You are conducting short-duration studies where discrete GH events are measured per administration

Choose CJC-1295 with DAC if…

Your research model requires sustained, tonic GH elevation over multiple days
You are studying GH deficiency models where continuous GH axis support is the experimental variable
Less frequent administration is optimal for your protocol design
You are investigating chronic IGF-1 elevation and its downstream tissue effects over extended timeframes

For a detailed comparison of half-life dynamics and GH pulse patterns between these two variants, see the CJC-1295 with DAC vs without DAC research comparison.

CJC1295 with DAC 5MG Nasal Spray for research →

Sermorelin vs CJC-1295 No DAC: Research Context

Researchers choosing between GHRH analogues for GH axis studies frequently encounter the Sermorelin vs CJC-1295 No DAC question. Sermorelin is the native GHRH 1-29 sequence without protective amino acid substitutions, making it highly susceptible to DPP-IV degradation and producing a briefer, less consistent GH pulse in research models. CJC-1295 No DAC’s enzymatic resistance provides greater signal consistency in experimental settings. As covered in the Sermorelin vs Ipamorelin research comparison, the choice of GHRH analogue meaningfully affects experimental reproducibility, and CJC-1295 No DAC has largely become the preferred GHRH analogue in contemporary GH research protocols.

Laboratory Applications and Experimental Design Notes

Researchers working with the CJC-1295 No DAC + Ipamorelin stack in 2026 are exploring several active areas:

GH pulsatility modeling: Using the stack to generate reproducible, dose-controlled GH pulses as a positive control in GH axis studies or to validate GH assay systems.
Metabolic phenotyping: Administering the stack to diet-induced obesity rodent models to observe changes in lean mass, adiposity, and insulin sensitivity, with IGF-1 as a surrogate endpoint.
Aging and somatopause research: Aged rodent models with blunted GH secretion have been used to assess whether GH secretagogue combinations can restore more youthful GH pulse architecture — a research area with implications for understanding age-related metabolic decline.
Sleep and circadian biology: GH is predominantly secreted during slow-wave sleep; some researchers are examining whether exogenous GHRH/GHRP administration timed to rest periods produces qualitatively different GH pulse patterns than wake-phase administration.
Combination research: Some investigators are studying the CJC-1295 No DAC + Ipamorelin stack alongside metabolic peptides such as those in the MOTS-C vs NAD+ mitochondrial research space to characterize additive effects on energy metabolism endpoints.

CJC 1295 No DAC + Ipamorelin 10MG (lyophilized) for research →

Where These Fit in Your Research Library

The CJC-1295 No DAC + Ipamorelin stack occupies a central role in GH axis research and connects naturally to several adjacent research areas available in our catalog:

CJC 1295 No DAC + Ipamorelin 10MG Nasal Spray → — Blended formulation for intranasal delivery research
IGF-1 LR3 1MG → — For downstream IGF-1 pathway research alongside GH secretagogue studies
Ipamorelin 10MG Nasal Spray → — Individual Ipamorelin for isolated GHSR-1a mechanism studies

Explore the full research peptide catalog at SourcePeptides.co →

Final Takeaway

The CJC-1295 No DAC + Ipamorelin stack represents one of the most mechanistically well-characterized GH secretagogue combinations in peptide research. By simultaneously engaging the GHRH-R and GHSR-1a pathways through distinct but convergent intracellular signaling cascades — cAMP/PKA and PLC/calcium respectively — the stack produces synergistic GH pulse amplification that neither peptide achieves independently. This dual-receptor model has made it a fundamental reference system in GH pulsatility studies, metabolic research, aging models, and IGF-1 axis investigations.

For researchers selecting between CJC-1295 No DAC and its DAC-bearing counterpart, the No DAC version’s short half-life and physiologically authentic pulse architecture make it the preferred choice for acute GH dynamics studies, while the combined stack remains the gold standard for maximizing GH pulse amplitude in preclinical GH axis research through 2026 and beyond.

Sources & Further Reading

Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.